It has been discovered that UPRmt is activated by the mevalonic acid route and the ceramide pathway, preventing amyloid–β (Aβ) aggregation and alleviating AD symptoms (Shen et al., 2019); Pink-1 activates ATFS-1-dependent UPRmt, which increases dopaminergic neuron survival and thereby alleviates Parkinson’s disease (Cooper et al., 2017); UPRmt suppresses the production of polyQ aggregates, which may help to prevent Huntington’s disease (Fu et al., 2019). Here, PINK1 is linked to Parkinson disease.